Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD

Research output: Research - peer-reviewArticle

  • 3 Citations

Abstract

Objective Premenstrual dysphoric disorder (PMDD), a more severe form of premenstrual syndrome (PMS), afflicts 5-8% of reproductive age women and results in significant functional impairment. We conducted a double-blind, placebo-controlled trial of adjunctive quetiapine in patients with PMS/PMDD who had inadequate response to selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor therapy for their symptoms. Methods A PMS/PMDD diagnosis was confirmed by 2-month prospective diagnostic assessment of PMS/PMDD using the Prospective Record of the Impact and Severity of Premenstrual Symptoms (PRISM) calendar. Women were randomized equally to receive quetiapine sustained-release (SR) or placebo (25-mg starting dose) during the luteal phase for 3 months. Outcome variables included the Hamilton Depression and Anxiety Scales, Clinical Global Impression Scale, and PRISM. Results Twenty women were enrolled in the treatment phase. Although the study was underpowered, greater reductions in luteal phase mood ratings were observed in the quetiapine group on the 17-item Hamilton Depression Rating Scale, Clinical Global Impression improvement rating, and PRISM daily score. The quetiapine group showed most improvement in symptoms of mood lability, anxiety, and irritability. Conclusion This small double-blind study suggests that adjunctive treatment with quetiapine SR may be a useful addition to selective serotonin reuptake inhibitor therapy in women with PMS/PMDD by reducing symptoms and improving quality of life.

LanguageEnglish (US)
Pages425-434
Number of pages10
JournalHuman Psychopharmacology
Volume30
Issue number6
DOIs
StatePublished - Nov 1 2015

Fingerprint

Premenstrual Syndrome
Placebos
Therapeutics
Premenstrual Dysphoric Disorder
Quetiapine Fumarate
Luteal Phase
Serotonin Uptake Inhibitors
Anxiety
Depression
Double-Blind Method
Quality of Life
Calendars
Serotonin and Noradrenaline Reuptake Inhibitors

Keywords

  • antidepressant medications
  • premenstrual dysphoric disorder
  • premenstrual syndrome
  • quetiapine
  • SNRIs
  • SSRIs

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

@article{5e1c6b94cbdb4fe1bcb46327cf464659,
title = "Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD",
abstract = "Objective Premenstrual dysphoric disorder (PMDD), a more severe form of premenstrual syndrome (PMS), afflicts 5-8% of reproductive age women and results in significant functional impairment. We conducted a double-blind, placebo-controlled trial of adjunctive quetiapine in patients with PMS/PMDD who had inadequate response to selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor therapy for their symptoms. Methods A PMS/PMDD diagnosis was confirmed by 2-month prospective diagnostic assessment of PMS/PMDD using the Prospective Record of the Impact and Severity of Premenstrual Symptoms (PRISM) calendar. Women were randomized equally to receive quetiapine sustained-release (SR) or placebo (25-mg starting dose) during the luteal phase for 3 months. Outcome variables included the Hamilton Depression and Anxiety Scales, Clinical Global Impression Scale, and PRISM. Results Twenty women were enrolled in the treatment phase. Although the study was underpowered, greater reductions in luteal phase mood ratings were observed in the quetiapine group on the 17-item Hamilton Depression Rating Scale, Clinical Global Impression improvement rating, and PRISM daily score. The quetiapine group showed most improvement in symptoms of mood lability, anxiety, and irritability. Conclusion This small double-blind study suggests that adjunctive treatment with quetiapine SR may be a useful addition to selective serotonin reuptake inhibitor therapy in women with PMS/PMDD by reducing symptoms and improving quality of life.",
keywords = "antidepressant medications, premenstrual dysphoric disorder, premenstrual syndrome, quetiapine, SNRIs, SSRIs",
author = "Christine Jackson and Brenda Pearson and Susan Girdler and Jacqueline Johnson and Hamer, {Robert M.} and Susan Killenberg and Samantha Meltzer-Brody",
year = "2015",
month = "11",
doi = "10.1002/hup.2494",
volume = "30",
pages = "425--434",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD

AU - Jackson,Christine

AU - Pearson,Brenda

AU - Girdler,Susan

AU - Johnson,Jacqueline

AU - Hamer,Robert M.

AU - Killenberg,Susan

AU - Meltzer-Brody,Samantha

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objective Premenstrual dysphoric disorder (PMDD), a more severe form of premenstrual syndrome (PMS), afflicts 5-8% of reproductive age women and results in significant functional impairment. We conducted a double-blind, placebo-controlled trial of adjunctive quetiapine in patients with PMS/PMDD who had inadequate response to selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor therapy for their symptoms. Methods A PMS/PMDD diagnosis was confirmed by 2-month prospective diagnostic assessment of PMS/PMDD using the Prospective Record of the Impact and Severity of Premenstrual Symptoms (PRISM) calendar. Women were randomized equally to receive quetiapine sustained-release (SR) or placebo (25-mg starting dose) during the luteal phase for 3 months. Outcome variables included the Hamilton Depression and Anxiety Scales, Clinical Global Impression Scale, and PRISM. Results Twenty women were enrolled in the treatment phase. Although the study was underpowered, greater reductions in luteal phase mood ratings were observed in the quetiapine group on the 17-item Hamilton Depression Rating Scale, Clinical Global Impression improvement rating, and PRISM daily score. The quetiapine group showed most improvement in symptoms of mood lability, anxiety, and irritability. Conclusion This small double-blind study suggests that adjunctive treatment with quetiapine SR may be a useful addition to selective serotonin reuptake inhibitor therapy in women with PMS/PMDD by reducing symptoms and improving quality of life.

AB - Objective Premenstrual dysphoric disorder (PMDD), a more severe form of premenstrual syndrome (PMS), afflicts 5-8% of reproductive age women and results in significant functional impairment. We conducted a double-blind, placebo-controlled trial of adjunctive quetiapine in patients with PMS/PMDD who had inadequate response to selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor therapy for their symptoms. Methods A PMS/PMDD diagnosis was confirmed by 2-month prospective diagnostic assessment of PMS/PMDD using the Prospective Record of the Impact and Severity of Premenstrual Symptoms (PRISM) calendar. Women were randomized equally to receive quetiapine sustained-release (SR) or placebo (25-mg starting dose) during the luteal phase for 3 months. Outcome variables included the Hamilton Depression and Anxiety Scales, Clinical Global Impression Scale, and PRISM. Results Twenty women were enrolled in the treatment phase. Although the study was underpowered, greater reductions in luteal phase mood ratings were observed in the quetiapine group on the 17-item Hamilton Depression Rating Scale, Clinical Global Impression improvement rating, and PRISM daily score. The quetiapine group showed most improvement in symptoms of mood lability, anxiety, and irritability. Conclusion This small double-blind study suggests that adjunctive treatment with quetiapine SR may be a useful addition to selective serotonin reuptake inhibitor therapy in women with PMS/PMDD by reducing symptoms and improving quality of life.

KW - antidepressant medications

KW - premenstrual dysphoric disorder

KW - premenstrual syndrome

KW - quetiapine

KW - SNRIs

KW - SSRIs

UR - http://www.scopus.com/inward/record.url?scp=84947045696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947045696&partnerID=8YFLogxK

U2 - 10.1002/hup.2494

DO - 10.1002/hup.2494

M3 - Article

VL - 30

SP - 425

EP - 434

JO - Human Psychopharmacology

T2 - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 6

ER -